Sanofi to divest its stake in the Yves Rocher Group

Thursday, July 5, 2012 02:21 PM

Global pharmaceutical company Sanofi has divested its direct and indirect stake of approximately 19.3% in the Yves Rocher Group, a company focused on cosmetics, home care products and clothing, to Société Financière des Laboratoires de Cosmétologie Yves Rocher, subject to certain closing conditions.

Upon closing of this transaction, which is expected to take place before the end of the third quarter, the Rocher family will control more than 95% of the Group's capital. The transaction consideration is undisclosed.

Sanofi acquired a stake in the Yves Rocher Group's capital in 1973 and divested part of its stake in the early 2000s.

"We are pleased to have been able to support the development of the Yves Rocher Group for about 40 years,” said Jérôme Contamine, executive vice president and CFO of Sanofi. "The decision to divest is in line with the Group’s objectives to focus on its strategic activities.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs